Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study.
Cardiac structure and function
Echocardiography
Heart failure (HF)
Sodium-glucose cotransporter type 2 inhibitors (SGLT-2i)
Journal
ESC heart failure
ISSN: 2055-5822
Titre abrégé: ESC Heart Fail
Pays: England
ID NLM: 101669191
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
revised:
27
01
2023
received:
20
11
2022
accepted:
07
02
2023
medline:
19
5
2023
pubmed:
17
3
2023
entrez:
16
3
2023
Statut:
ppublish
Résumé
Sodium-glucose cotransporter type 2 inhibitors (SGLT-2i) represent a unique class of anti-hyperglycaemic agents for type 2 diabetes mellitus that selectively inhibit renal glucose reabsorption, thereby increasing urinary excretion of glucose. Several studies have demonstrated the cardioprotective effects of SGLT-2i in patients with heart failure (HF), unrelated to its glucosuric effect. It is unclear whether the benefits of SGLT-2i therapy also rely on the improvement of left ventricular (LV) and/or right ventricular (RV) function in patients with HF. This study aimed to evaluate the effect of SGLT-2i on LV and RV function through conventional and advanced echocardiographic parameters with a special focus on RV function in patients with HF. The Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure (BEGIN-HF) study is an international multicentre, prospective study that will evaluate the effect of SGLT-2i on echocardiographic parameters of myocardial function in patients with chronic stable HF across the left ventricular ejection fraction (LVEF) spectrum. Patients with New York Heart Association Class II/III symptoms, estimated glomerular filtration rate > 25 mL/min/1.73 m The BEGIN-HF will determine whether SGLT-2i therapy improves LV and/or RV function by conventional and advanced echocardiography in patients with HF irrespective of LVEF.
Identifiants
pubmed: 36924023
doi: 10.1002/ehf2.14331
pmc: PMC10192273
doi:
Substances chimiques
Sodium-Glucose Transporter 2 Inhibitors
0
Glucose
IY9XDZ35W2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2066-2073Informations de copyright
© 2023 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
Références
Card Fail Rev. 2017 Apr;3(1):7-11
pubmed: 28785469
J Cardiol. 2018 May;71(5):471-476
pubmed: 29415819
Am J Hypertens. 2019 Apr 22;32(5):452-459
pubmed: 30689697
Am Heart J. 2018 Jun;200:83-89
pubmed: 29898853
J Am Heart Assoc. 2021 Aug 3;10(15):e019545
pubmed: 34325519
Endocrinol Metab (Seoul). 2019 Jun;34(2):106-116
pubmed: 31099200
J Cardiovasc Med (Hagerstown). 2019 Dec;20(12):797-808
pubmed: 31609849
Int J Cardiol Heart Vasc. 2019 Jan 11;22:102-104
pubmed: 30963090
Diabetes Care. 2020 Jun;43(6):1356-1359
pubmed: 32245746
J Am Coll Cardiol. 2021 Jan 26;77(3):243-255
pubmed: 33197559
ESC Heart Fail. 2023 Jun;10(3):2066-2073
pubmed: 36924023
Eur Heart J. 2021 Dec 21;42(48):4901
pubmed: 34649282
Heart Fail Rev. 2022 Jul;27(4):1147-1163
pubmed: 34097173
Cardiovasc Drugs Ther. 2022 Dec;36(6):1157-1164
pubmed: 34519913
Cardiovasc Diabetol. 2020 Feb 8;19(1):13
pubmed: 32035482
JAMA Cardiol. 2021 Jul 1;6(7):836-840
pubmed: 33404637
Circulation. 2021 Jan 26;143(4):326-336
pubmed: 33081531
Cardiovasc Drugs Ther. 2019 Aug;33(4):435-442
pubmed: 31321581
Cardiovasc Drugs Ther. 2018 Apr;32(2):213-222
pubmed: 29679303
Eur J Heart Fail. 2019 Jul;21(7):862-873
pubmed: 31033127
Heart Fail Rev. 2023 May;28(3):733-744
pubmed: 34379224
Eur Heart J. 2020 Sep 21;41(36):3421-3432
pubmed: 32578850
Diabetes Care. 2016 Dec;39(12):e212-e213
pubmed: 27679584
J Am Coll Cardiol. 2003 Mar 19;41(6):1021-7
pubmed: 12651052
N Engl J Med. 2015 Nov 26;373(22):2117-28
pubmed: 26378978
Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704
pubmed: 29937267
Circulation. 2021 Feb 9;143(6):516-525
pubmed: 33186500
Front Cardiovasc Med. 2021 May 05;8:665797
pubmed: 34026873
J Am Soc Echocardiogr. 2009 Jul;22(7):814-9
pubmed: 19505794
J Am Coll Cardiol. 2022 Apr 26;79(16):1549-1561
pubmed: 35450571
Cardiovasc Diabetol. 2019 Feb 2;18(1):15
pubmed: 30710997
Circulation. 2019 Nov 19;140(21):1693-1702
pubmed: 31434508
Eur J Heart Fail. 2021 Aug;23(8):1290-1295
pubmed: 33928732
J Am Soc Echocardiogr. 2015 Jan;28(1):1-39.e14
pubmed: 25559473